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Volume 59, Number 6S Abstracts 33Sstudies, and clinical implantation of the graft. Banked hu-
man aortic smooth muscle cells were cultured in bioreac-
tors in vitro to produce vascular tissue grafts, and a
decellularization process was subsequently used to remove
immunogenic cellular antigens. Arteriovenous grafts were
implanted into nonhuman primates for up to 6 months
and were evaluated for patency, durability, cannulation,
rejection, and cellular repopulation. In addition, these
grafts were evaluated for long-term arterial reconstruction
in a canine model, using canine-derived grafts. In animal
studies, histologic analysis demonstrated evidence of host
vascular cell migration into grafts and endothelialization.
Little intimal hyperplasia was observed in animal studies.
These preclinical studies supported initiation of clinical
trials.
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Clinical Outcomes and Cost Effectiveness of Initial
Treatment Strategies for Non-Embolic Acute Limb
Ischemia in Real-Life Clinical Settings
Anthony J. Comerota1, Varun Vaidya2, Fedor Lurie1.
1Jobst Vascular Institute, Toledo, Ohio; 2University of
Toledo College of Pharmacy, Toledo, Ohio
Objectives: Optimal initial treatment for patients with
acute limb ischemia (ALI) remains undeﬁned. Although
clinical outcome data are inconsistent, catheter-directed
thrombolysis (CDT) with tissue plasminogen activator is
increasingly used. Patient-level analysis combining clinical
and economic data in a real-life setting is lacking. This
study compares clinical outcomes and cost effectivenessTable. Clinical and economic outcomes
Variable CDT (n ¼ 68) CDT + A (n ¼ 16) Open
AFS (%/N) 94/64 87/14
Readmissions (%/N) 16/11 31/5
Mortality (%/N) 0 6/1
Major bleed (%/N) 3/2 0
Reinterventions (%/N) 62/42 33/5
Initial hosp costs, $
Mean 31,804 27,779
SE 2436 5035
Readmission cost ($)
Mean 20,441 26,844
SE 4684 7306
Total cost
Mean 34,840 37,002
SE 2725 5628of initial treatment strategies for non-embolic ALI using
real-life patient-level data.
Methods: Medical records and hospital cost data were
analyzed for non-embolic ALI patients treated in four hos-
pitals over 3 years. A cost-effectiveness analysis was per-
formed using a decision tree analytical model. All costs
were valued based on cost-to-charge ratios.
Results: In 205 patients, initial treatments were CDT
alone (68) or with angioplasty (16), open surgery (60),
endovascular (33), and hybrid (28). Clinical and economic
outcomes are summarized in the Table. Although clinical
outcomes did not differ signiﬁcantly between groups, rein-
tervention rates during hospital stay, readmission rates, and
costs were highest in the CDT group. More than one re-
intervention was needed in 16% of patients in the CDT
group.
Conclusions: In this real-life study, initial treatment
of non-embolic limb ALI with currently available CDT
options was associated with greater healthcare resource
consumption and cost compared to other initial treatment
options.
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Lessons Learned in the Surgical Treatment of
Neurogenic Thoracic Outlet Syndrome over 10 years
Kendall Likes, Megan S. Orlando, Serene Mirza, Quinn
Salditch, Anne Cohen, Ying W. Lum, Thomas Reifsnyder,
Julie Freischlag. Johns Hopkins Medical Institutions,
Baltimore, Md
Objectives: To evaluate our extensive experience in
the treatment of patients with neurogenic thoracic outlet
syndrome (NTOS) who underwent ﬁrst rib resection and
scalenectomy (FRRS) over a decade.
Methods: Patients treated with FRRS for NTOS from
2003 to 2013 were retrospectively reviewed using a pro-
spectively maintained database.
Results: Over the 10 years, 286 patients underwent
308 FRRS. During the ﬁrst 5-year period, 127 FRRS
were performed (96 female, 31 male), with an average
age of 36.9 years. During the second 5-year period, 181
FRRS were performed (143 female, 38 male), with an
average age of 33 years. Twenty-four children (age #18
years) underwent FRRS; nine during the ﬁrst 5 years andSurg (n ¼ 60) Endovasc (n ¼ 33) Hybrid (n ¼ 28) P
95/57 100/33 100/28 NS
7/4 6/2 3/1 <.05
1/1 0 0 NS
1/1 0 0 NS
7/4 12/4 18/5 <.00001
.01
16,636 20,751 21,134
2595 3494 3850
.05
7434 24,409 4156
9847 11,235 18,117
.0001
17,758 21,916 21,220
2921 3911 4309
